Ventus Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating VENT-02, an Oral, Brain-Penetrant NLRP3 Inhibitor, in Parkinson’s Disease

https://financialpost.com/pmn/business-wire-news-releases-pmn/ventus-therapeutics-announces-first-patient-dosed-in-phase-2a-clinical-trial-evaluating-vent-02-an-oral-brain-penetrant-nlrp3-inhibitor-in-parkinsons-disease